All these findings suggest that miR-134 downregulation promotes doxorubicin resistance in breast cancer and that the process is mediated through the regulation of the ABCC1 gene, which should be further explored in a therapeutic setting[162]. The gene discussed is ABCC1; the disease is breast cancer.